AIM:To evaluate the efficacy of intravitreal injection of triamcinolone acetonide and bevacizumab for macular edema after cataract surgeries, providing clinical reference for the safety and efficacy of treatments.

METHODS:Ninety-two patients(92 eyes)diagnosed as macular edema were chosen for the study in the department of ophthalmology from March 2012 to March 2014 in our hospital. They were divided into two groups according to different intravitreal injection drugs, the triamcinolone acetonide group with 44 cases(44 eyes)and the bevacizumab group with 48 cases(48 eyes). They were followed up for 9mo after surgeries, and the best-corrected visual acuity(BCVA), the mean central retinal thickness, macular capillary angiographic results and intraocular pressure(IOP)were compared between the two groups at the same time points.

RESULTS:The BCVA of the two groups were both improved postoperatively, but there was no significant differences between the groups in the followed up for 9mo(P>0.05). By repeated measures analysis of variance, there was no significant difference on the central retinal macular thickness between the two groups(P>0.05). The differences on the central retinal macular thickness between the preoperative and each time point postoperative in the triamcinolone acetonide group were statistically significant(t=9.16,8.27,5.44,5.87,4.62, P<0.05), and the central retinal thickness at each time point postoperative was lower than that preoperative in the bevacizumab group, and the differences were statistically significant(t=8.11,5.12,4.16,3.27,2.88, P<0.05).Seven patients had increased IOP in the triamcinolone acetonide group, and became glaucoma, but there was no ocular abnormalities in the bevacizumab group.

CONCLUSION:Triamcinolone acetonide and bevacizumab can improve visual acuity and capillary leakage in patients with macular edema, but bevacizumab which can not cause increased IOP, can prevent other complications, with more security.